Gluconic Acid

Gluconic Acid

SCHEMBL23804124

O=C(O)C(=O)O.O=C(O)C(O)C(O)C(O)C(O)CO.[MgH2].[MgH2]

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHE

The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.86
LMNA P02545 2/20 0.59
USP2 O75604 1/20 0.54
SLCO1B1 Q9Y6L6 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.50
TDP1 Q9NUW8 1/20 0.48
TSHR P16473 2/20 0.46
CYP2C9 P11712 1/20 0.46
OR51E2 Q9H255 1/20 0.39
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 1/20 0.33
PGD P52209 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gluconic Acid SCHEMBL23804123 1.00 PDE4A (0.86) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL27590197 0.98 PDE4A (0.91) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL1001814 0.98 PDE4A (0.91) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL7770544 0.95 PDE4A (0.86) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL28022593 0.95 PDE4A (0.95) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL1532403 0.95 PDE4A (0.95) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL6536096 0.95 PDE4A (0.95) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL9017591 0.95 PDE4A (0.95) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL14894063 0.93 PDE4A (0.91) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL21462394 0.93 PDE4A (0.91) PDE4ALMNAUSP2SLCO1B1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213644-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF BONE-RELATED DISEASE OR DISORDER GABET, Yankel (IL) 2025-07-03 US disclosed
EP-4392053-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF BONE-RELATED DISEASE OR DISORDER Gabet, Yankel (IL) 2024-07-03 EP disclosed
WO-2023026280-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF BONE-RELATED DISEASE OR DISORDER RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2023-03-02 WO disclosed
WO-2021181379-A1 COMPOSITIONS AND METHODS FOR TREATING OSTEOLYSIS RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2021-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213644-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF BONE-RELATED DISEASE OR DISORDER BMP2, CALCB, CALCA PDE4A 2510/4885LMNA 2800/4885USP2 3102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.